{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:36:55Z","timestamp":1791988615101,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.clinthera.2007.07.022","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T11:24:06Z","timestamp":1188991446000},"page":"1338-1353","source":"Crossref","is-referenced-by-count":158,"title":["Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors"],"prefix":"10.1016","volume":"29","author":[{"given":"Val R.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Leggas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.07.022_bib1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdj133","article-title":"Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: A review","volume":"17","author":"Schoffski","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib2","year":"2006","journal-title":"Cancer facts & figures"},{"key":"10.1016\/j.clinthera.2007.07.022_bib3","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2007.07.022_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/sj.bjc.6602978","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"94","author":"Patel","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2007.07.022_bib5","doi-asserted-by":"crossref","unstructured":"Houk BE, Amantea M, Motzer RJ, et al. Pharmacokinetics (PK) and efficacy ofsunitinib in patients with metastatic renal cell carcinoma (mRCC). Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 4531.","DOI":"10.1200\/jco.2006.24.18_suppl.4531"},{"key":"10.1016\/j.clinthera.2007.07.022_bib6","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Presented at: ASCO Annual Meeting; May 13-17, 2005; Orlando, Fla. Abstract 4508.","DOI":"10.1200\/jco.2005.23.16_suppl.4508"},{"key":"10.1016\/j.clinthera.2007.07.022_bib7","series-title":"Sunitinib","year":"2006"},{"key":"10.1016\/j.clinthera.2007.07.022_bib8","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/j.1572-0241.2005.50650_6.x","article-title":"Epidemiology of GIST","volume":"100","author":"Blanke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/cncr.20862","article-title":"Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden","volume":"103","author":"Nilsson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2007.07.022_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/106689690000800105","article-title":"Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors","volume":"8","author":"Rubin","year":"2002","journal-title":"Int J Surg Patkol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib11","first-page":"577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Sdence"},{"key":"10.1016\/j.clinthera.2007.07.022_bib12","first-page":"3034","article-title":"Approval summary: Imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2007.07.022_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2005.40709.x","article-title":"The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1458 cases from 1992 to 2000","volume":"100","author":"Tran","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib14","doi-asserted-by":"crossref","unstructured":"Blanke CD, Demetri GD, Von Mehren M, et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 9528.","DOI":"10.1200\/jco.2006.24.18_suppl.9528"},{"key":"10.1016\/j.clinthera.2007.07.022_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","article-title":"Discovery of 5-[5-fluoro-2-oxo-l,2-dihydroin dol-(3Z)-ylidenemethyl]-2,4-dimethyl-1 H- pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase","volume":"46","author":"Sun","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2007.07.022_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hall-marks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Ceil"},{"key":"10.1016\/j.clinthera.2007.07.022_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","article-title":"Tumor induction of VEGF promoter activity in stromal cells","volume":"94","author":"Fukumura","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2007.07.022_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1096\/fj.01-0700com","article-title":"SU6668 inhibits FIk-1\/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice","volume":"16","author":"Laird","year":"2002","journal-title":"FASEBJ"},{"key":"10.1016\/j.clinthera.2007.07.022_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2007.07.022_bib20","first-page":"1377","article-title":"Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma","volume":"143","author":"Sundberg","year":"1993","journal-title":"AmJ Pathol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib21","first-page":"1011","article-title":"Preclinical evaluation of the tyrosine kinase inhibitor 5Ul1248 as a single agent and in combination with \u201cstandard of care\u201d therapeutic agents for the treatment of breast cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clinthera.2007.07.022_bib22","first-page":"327","article-title":"In vivo antitumor activiW ofSU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/ pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2007.07.022_bib23","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SUI 1248 in acute myeloid leukemia patients","volume":"9","author":"O'Farrell","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2007.07.022_bib24","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SUl1248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2007.07.022_bib25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2007.07.022_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SUl1248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2174\/138945005774574498","article-title":"Targeted agents for the treatment of advanced renal cell carcinoma","volume":"6","author":"Staehler","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.clinthera.2007.07.022_bib28","first-page":"664","article-title":"Novel agents for the treatment of advanced kidney cancer","volume":"2","author":"Cooney","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1464-410X.2005.05616.x","article-title":"Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development","volume":"96","author":"Rini","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2007.07.022_bib30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.cad.0000167901.58877.a3","article-title":"Novel treatment strategies in clear-cell metastatic renal cell carcinoma","volume":"16","author":"van Spronsen","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2007.07.022_bib31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/96.17.1270","article-title":"Three molecularly targeted drugs tested in kidney cancer clinical trials","volume":"96","author":"Tuma","year":"2004","journal-title":"J Nail Cancer Inst"},{"key":"10.1016\/j.clinthera.2007.07.022_bib32","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.07.022_bib33","unstructured":"Suppiah R, Finke J, Rini BI, et al. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1\/T helper 2 (Thl\/Th2) bias. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 2526."},{"key":"10.1016\/j.clinthera.2007.07.022_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00001813-200603000-00015","article-title":"Effect of food on the pharmacokinetics ofsunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects","volume":"17","author":"Bello","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2007.07.022_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and anti-tumor activiW of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib36_1","unstructured":"Center for Drug Evaluation and Research. Approval package for: Application number NDA 21-938 (GIST), NDA 21-968 (mRCC). Medical review(s)"},{"key":"10.1016\/j.clinthera.2007.07.022_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/13543784.15.5.553","article-title":"Sunitinib malate for the treatment of solid tumours: A review of current clinical data","volume":"15","author":"Motzer","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2007.07.022_bib38","unstructured":"Washington C, Eli M, Bello C, et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in caucasian and Asian healthy subjects. Presented at: ASCO Annual Meeting; May 31-June 3, 2003; Chicago, III. Abstract 553."},{"key":"10.1016\/j.clinthera.2007.07.022_bib39","doi-asserted-by":"crossref","unstructured":"Bello C, Houk B, Sherman L, et al. Effect ofriFampin on the pharmacokinetics of SU11248 in healthy volunteers. Presented at: ASCO Annual Meeting; May 13-17, 2005; Orlando, Fla. Abstract 3078.","DOI":"10.1200\/jco.2005.23.16_suppl.3078"},{"key":"10.1016\/j.clinthera.2007.07.022_bib40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic Factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Nail Cancer Inst"},{"key":"10.1016\/j.clinthera.2007.07.022_bib42","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-06-0919","article-title":"Blood-based biomarkers of SUl1248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor","volume":"13","author":"Norden-ZFoni","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2007.07.022_bib43","doi-asserted-by":"crossref","unstructured":"Deprimo SE, Friece C, Huang X, et al. EFFect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 578.","DOI":"10.1200\/jco.2006.24.18_suppl.578"},{"key":"10.1016\/j.clinthera.2007.07.022_bib44","unstructured":"Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety ofsunitinib malate (SU11 248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 4522.44"},{"key":"10.1016\/j.clinthera.2007.07.022_bib45","doi-asserted-by":"crossref","unstructured":"Maki RG, FletcherJA, Heinrich MC, et al. Results from a continuation trial oF SU11248 in patients (pts) with imatinib (IM)-resistant gas- trointestinal stromal tumor (GIST). Presented at: ASCO Annual Meeting; May 13-17, 2005; Orlando, Fla. Abstract 9011.","DOI":"10.1200\/jco.2005.23.16_suppl.9011"},{"key":"10.1016\/j.clinthera.2007.07.022_bib46","doi-asserted-by":"crossref","unstructured":"George S, Casali PG, Blay J, et al. Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 9532.","DOI":"10.1200\/jco.2006.24.18_suppl.9532"},{"key":"10.1016\/j.clinthera.2007.07.022_bib47","unstructured":"Morgan JA, Garrett CR, Schutte HJ, et al. Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a \u201ctreatment-use\u201d trial. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 9540."},{"key":"10.1016\/j.clinthera.2007.07.022_bib48","unstructured":"Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of suniti-nib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 7001."},{"key":"10.1016\/j.clinthera.2007.07.022_bib49","doi-asserted-by":"crossref","unstructured":"Kulke M, Lenz H J, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety oFSU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Presented at: ASCO Annual Meeting; May 13-17, 2005; Orlando, Fla. Abstract 4008.","DOI":"10.1200\/jco.2005.23.16_suppl.4008"},{"key":"10.1016\/j.clinthera.2007.07.022_bib50","doi-asserted-by":"crossref","unstructured":"Miller KD, Burnstei H J, Elias AD, et al. Phase II study of SUl1248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Presented at: ASCO Annual Meeting; May 13-17, 2005; Orlando, Fla. Abstract 563.","DOI":"10.1200\/jco.2005.23.16_suppl.563"},{"key":"10.1016\/j.clinthera.2007.07.022_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.07.022_bib52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.07.022_bib53","doi-asserted-by":"crossref","unstructured":"Casali PG, Garrett CR, Blackstein ME, et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 9513.","DOI":"10.1200\/jco.2006.24.18_suppl.9513"},{"key":"10.1016\/j.clinthera.2007.07.022_bib54","doi-asserted-by":"crossref","unstructured":"Janeway KA, Matthews DC, Butrynski JE, et al. Sunitinib treatment of pediatric metastatic GIST after Failure ofimatinib. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 9519.","DOI":"10.1200\/jco.2006.24.18_suppl.9519"},{"key":"10.1016\/j.clinthera.2007.07.022_bib55","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2007.07.022_bib56","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/jnci\/djg101","article-title":"Hemostatic regulators of tumor angiogenesis: A source of anti-angiogenic agents for cancer treatment?","volume":"95","author":"Daly","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2007.07.022_bib57","doi-asserted-by":"crossref","unstructured":"Shaheen PE, Tamasker IR, Salas RN, et al. Thyroid Function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at: ASCO Annual Meeting; June 2-6, 2006; Atlanta, Ga. Abstract 4605.","DOI":"10.1200\/jco.2006.24.18_suppl.4605"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807002147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807002147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T09:04:00Z","timestamp":1587891840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807002147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0149291807002147"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.07.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}